<DOC>
	<DOCNO>NCT01047592</DOCNO>
	<brief_summary>Hypofunction N-methyl-D-aspartate ( NMDA ) receptor implicate pathophysiology schizophrenia . To date , several report trial adjuvant NMDA-enhancing agent , include glycine sarcosine ( glycine transporter I inhibitor ) , demonstrate clinical benefit schizophrenia patient . This project aim compare efficacy safety sarcosine combination sarcosine BE , adjunctive therapy schizophrenia , explore possible synergistic effect . Sixty chronic schizophrenic inpatient enrol 12-week double-blind , placebo-controlled trial . The participant receive stable antipsychotic regimen concomitant sarcosine ( 2 g/d ) ( N=21 ) , sarcosine ( 2 g/d ) + BE ( 1 g/d ) ( N=21 ) , placebo ( N=21 ) . Measures clinical efficacy side-effects determine every 3 week . Measures cognitive function determine begin end study . The efficacy three group compare , characteristic better responder analyze .</brief_summary>
	<brief_title>Treatment N-methyl-D-aspartate ( NMDA ) Enhancers Schizophrenia</brief_title>
	<detailed_description>We measure clinical efficacy every 3 week treatment . At begin end trial , We utilize battery test assess effect treatment cognitive functions.The side effect assessment also perform every 3 week . Side effect assessment include Simpson-Angus Rating Scale extrapyramidal side-effects , Abnormal Involuntary Movement Scale ( AIMS ) dyskinesia , Barnes Akathisia Scale . Systemic side effect review apply Udvalg Kliniske Undersogelser ( UKU ) Side-effects Rating Scale . DAAO level , routine laboratory test , include CBC , biochemistry , urine analysis , EKG , check baseline end week 12 . To compare metabolic syndrome parameter among group , body mass index , hip size , waist size , blood pressure , fast blood sugar , triglyceride , total-cholesterol check baseline end study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>N-Methylaspartate</mesh_term>
	<criteria>The participant fulfill criterion schizophrenia accord Diagnostic Statistic Manual , fourth edition ( DSMIV ) . The participant remain stable schizophrenic symptom receive stable antipsychotic regimen last 8 week enrollment . The participant agree participate study provide informed consent . History alcohol substance dependence , history epilepsy , head trauma CNS diseases , history major , untreated medical disease , mental retardation , pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>cognitive function</keyword>
	<keyword>N-methyl-D-aspartate receptor</keyword>
</DOC>